Compare Northrop Grumman Corporation (NOC) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs uniQure N.V. Ordinary Shares — how do they compare? Northrop Grumman Corporation trades at $502 (market cap $70.42B), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: Northrop Grumman Corporation is far larger — about 48.6× uniQure N.V. Ordinary Shares's market cap, and Northrop Grumman Corporation pays a 1.99% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 82 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NOC | QURE | |
|---|---|---|
Market Cap | $70.42B | $1.45B |
Volume | 1,218,886 | 3,323,243 |
Sector | Industrials | Health |
52-Week High | $768.02 | $70.59 |
52-Week Low | $473.46 | $9.03 |
Typical Hold Time | 82 Days | 0 Days |
Enterprise Value | $84.40B | $707.46M |
Dividend Yield | 1.99% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
